ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 161 filers reported holding ARCUS BIOSCIENCES INC in Q1 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $757,759 | -41.9% | 42,215 | -15.4% | 0.00% | -50.0% |
| Q3 2022 | $1,305,000 | -79.9% | 49,891 | -68.9% | 0.00% | -71.4% |
| Q4 2021 | $6,489,000 | +171.8% | 160,336 | +134.3% | 0.01% | +180.0% |
| Q3 2021 | $2,387,000 | -36.9% | 68,445 | -50.3% | 0.01% | -44.4% |
| Q2 2021 | $3,783,000 | +297.8% | 137,752 | +306.7% | 0.01% | +350.0% |
| Q1 2021 | $951,000 | -82.1% | 33,869 | -83.4% | 0.00% | -86.7% |
| Q4 2020 | $5,302,000 | -47.7% | 204,233 | -65.5% | 0.02% | -58.3% |
| Q3 2020 | $10,146,000 | +11.7% | 591,946 | +61.2% | 0.04% | -20.0% |
| Q2 2020 | $9,087,000 | +1106.8% | 367,318 | +576.8% | 0.04% | +650.0% |
| Q1 2020 | $753,000 | -40.3% | 54,271 | -56.6% | 0.01% | +50.0% |
| Q4 2019 | $1,262,000 | +322.1% | 124,973 | +280.4% | 0.00% | +300.0% |
| Q3 2019 | $299,000 | -14.3% | 32,850 | -25.1% | 0.00% | 0.0% |
| Q2 2019 | $349,000 | – | 43,883 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |